SCHEDULE: Deep Track Funds Acquire 14.9% Stake in LB Pharmaceuticals

Deep Track Capital and its affiliated funds have collectively acquired a 14.9% beneficial ownership stake in LB Pharmaceuticals Inc. following its IPO.

Summary

• Deep Track Capital and its affiliates, Deep Track Biotechnology Master Fund, Ltd. (DTBMF) and Deep Track Special Opportunities Fund, LP (DTSOF), reported beneficial ownership of 3,352,804 shares of LB Pharmaceuticals Inc. common stock.
• This aggregate ownership represents 14.9% of the Issuer's common stock outstanding after its Initial Public Offering (IPO).
• DTBMF initially invested $25,000,000 in Series C Preferred Stock, which converted into 686,138 common shares upon the IPO.
• On September 12, 2025, DTBMF purchased an additional 2,000,000 common shares, and DTSOF purchased 666,666 common shares, both at $15.00 per share in the IPO.
• The total shares outstanding after the IPO are 22,442,989.
• The acquisitions were made for investment purposes, with the Reporting Persons intending to continuously review their investment and potentially engage with management or adjust their holdings.
• Rebecca Luse, a Managing Director at Deep Track Capital, serves on the Board of Directors of LB Pharmaceuticals Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant and strategic investment by a specialized fund in LB Pharmaceuticals Inc. post-IPO, including board representation, which is generally a positive signal of institutional confidence. The purpose is purely for investment, with no immediate negative intentions stated.

Positives

• A significant institutional investor, Deep Track Capital, has taken a substantial 14.9% stake in LB Pharmaceuticals Inc., indicating confidence in the company's prospects.
• The investment includes a prior $25,000,000 investment in Series C Preferred Stock, demonstrating a long-term commitment.
• Deep Track Capital has a representative, Rebecca Luse, on the Issuer's Board of Directors, which could provide strategic guidance and oversight.

Negatives

• The filing, being a Schedule 13D, primarily reports ownership and does not contain explicit negative information regarding the company's operational performance or prospects.

Risks

• The Reporting Persons may sell or dispose of some or all of their securities, or acquire additional securities, based on various factors including market conditions, the Issuer's business, and other investment opportunities, which could impact share price volatility.

Future Outlook

The Reporting Persons intend to continuously review their investment in LB Pharmaceuticals Inc. and may engage in discussions with management, the board, and other shareholders. They may also acquire additional securities or dispose of existing holdings based on various market and company-specific factors.

Management Comments

• The Reporting Persons acquired the securities reported herein for investment purposes.
• The Reporting Persons intend to review on a continuing basis the investments in the Issuer by the Reporting Persons.
• The Reporting Persons may engage in discussions with management, the board of directors of the Issuer, other shareholders of the Issuer and other relevant parties concerning the Reporting Persons' investment in the Issuer's securities.

Industry Context

This filing indicates a significant institutional investment in a newly public biotechnology or pharmaceutical company, which is common in the sector as companies seek capital for R&D and commercialization. The involvement of a specialized biotechnology fund like Deep Track Capital suggests a focused interest in the life sciences industry.

Comparison to Industry Standards

• A 14.9% stake by an institutional investor post-IPO is a substantial position, often seen as a vote of confidence, especially in the biotech sector where early-stage companies rely heavily on institutional backing.
• The inclusion of a board representative from the investing firm (Rebecca Luse from Deep Track Capital) is a common practice for significant institutional investors, allowing for direct influence and oversight, similar to venture capital or private equity investments in public companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The significant institutional investment and board representation by Deep Track Capital could be viewed positively, potentially stabilizing the stock and providing strategic guidance. However, the possibility of future sales or acquisitions by the Reporting Persons introduces potential volatility.
• Management/Board: The presence of a Deep Track Capital representative on the board means increased oversight and potential influence on strategic decisions.

Next Steps

• Reporting Persons will continuously review their investment in LB Pharmaceuticals Inc.
• Reporting Persons may engage in discussions with management, the board, other shareholders, and relevant parties.
• Reporting Persons may seek to sell or dispose of some or all of the Issuer's securities.
• Reporting Persons may seek to acquire additional securities of the Issuer.

Key Dates

Recommendation

Deep Track Capital's significant 14.9% stake and board representation in LB Pharmaceuticals Inc. post-IPO is a strong vote of confidence from a specialized biotechnology investor. This institutional backing could provide stability and strategic direction. However, as a Schedule 13D primarily details ownership and investment intent rather than operational performance or financial results, a 'hold' recommendation is appropriate. Investors should monitor future developments, including the company's financial performance and Deep Track Capital's ongoing involvement, before making further investment decisions.

Keywords

LB Pharmaceuticals Inc, Deep Track Capital, Schedule 13D, Beneficial Ownership, IPO, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals, Equity Stake